SSG
FULC icon

Summit Securities Group’s Fulcrum Therapeutics FULC Stock Holding History

Summit Securities Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53.5K Buy
+6,975
New +$64.7K 0.01% 381
2025
Q4 		– Sell
-2,917
Closed -$26.8K – 1090
2025
Q3 		$26.8K Buy
+2,917
New +$21.1K 0.01% 715

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Summit Securities Group's FULC Position: Q1 2026 in Review

Summit Securities Group opened a new position in Fulcrum Therapeutics (FULC) in Q1 2026: 6,975 shares worth $53.5K. The stake represents 0.01% of the portfolio and ranks #381 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in FULC as recently as Q3 2025.

Summit Securities Group first reported a position in FULC in Q3 2025 and has held it in 2 quarters since. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Summit Securities Group held 6,975 shares of Fulcrum Therapeutics worth $53.5K as of Q1 2026.
  • Fulcrum Therapeutics was a new Summit Securities Group position in Q1 2026.
  • Fulcrum Therapeutics made up 0.01% of Summit Securities Group's portfolio in Q1 2026, its #381 holding.
  • Summit Securities Group first reported a position in Fulcrum Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.